Bayer AG (BAYN) Given Consensus Rating of “Buy” by Analysts

Bayer AG (FRA:BAYN) has earned an average recommendation of “Buy” from the twenty-three brokerages that are currently covering the firm, Marketbeat.com reports. Eight analysts have rated the stock with a hold rating and fifteen have issued a buy rating on the company. The average twelve-month price objective among brokers that have issued a report on the stock in the last year is €100.34 ($116.68).

BAYN has been the topic of a number of research analyst reports. JPMorgan Chase & Co. reiterated a “buy” rating on shares of Bayer in a research note on Thursday, August 30th. Berenberg Bank set a €113.00 ($131.40) price target on shares of Bayer and gave the stock a “buy” rating in a research report on Monday, August 27th. UBS Group set a €130.00 ($151.16) price target on shares of Bayer and gave the stock a “buy” rating in a research report on Friday, August 17th. Deutsche Bank set a €137.00 ($159.30) price target on shares of Bayer and gave the stock a “buy” rating in a research report on Wednesday, August 22nd. Finally, DZ Bank restated a “neutral” rating on shares of Bayer in a research report on Friday, August 24th.

FRA:BAYN traded up €0.28 ($0.33) during midday trading on Friday, reaching €76.10 ($88.49). The stock had a trading volume of 4,021,405 shares. Bayer has a 1-year low of €91.58 ($106.49) and a 1-year high of €123.82 ($143.98).

About Bayer

Bayer Aktiengesellschaft operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, Crop Science, and Animal Health segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents.

Featured Article: Diversification For Individual Investors

Analyst Recommendations for Bayer (FRA:BAYN)

Receive News & Ratings for Bayer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bayer and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply